Drugs / HA121-28
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05072535 | Oct → Dec 2021 | — | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03994484 | Oct 2018 → Dec 2022 | neoplasm | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05117658 | Feb 2022 → Oct 2023 | non-small cell lung carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04787328 | Jul 2021 → Mar 2023 | medullary thyroid gland carcinoma | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04784520 | Jun 2021 → Dec 2022 | biliary tract cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-11-06 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - THE GROUP'S "HA121-28" AND "ALPROSTADIL LIPOSOME INJECTION" WERE GRANTED CLINICAL TRIAL APPROVALS irasia.com ↗
THE GROUP’S “HA121-28”AND “ALPROSTADIL LIPOSOME INJECTION” WERE GRANTED CLINICAL TRIAL APPROVALS |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-11-06 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - THE GROUP'S "HA121-28" AND "ALPROSTADIL LIPOSOME INJECTION" WERE GRANTED CLINICAL TRIAL APPROVALS irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HA121-28 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05072535 ↗ |
| Route | Oral | “Participants will receive oral HA121-28 at a starting dose of 25 mg once daily at the 1st day in 0 cycle and for 21 days on a 28-day treatment cycle” NCT03994484 ↗ |